pharmaphorum8y
Sanofi and BI finalise swap to create market leading consumer and animal health divisions
Boehringer Ingelheim’s integration of Sanofi’s Merial into its animal health business will more than double its sales to approximately €3.8 bn based upon 2015 global sales. The transaction ...
pharmaphorum6d
Boosted by new drugs, Boehringer shrugs off patent expiry
As the EU patent expires on its flagship respiratory diseases product, Spiriva, Boehringer Ingelheim is looking ... its animal health acquisition, Merial, bought from Sanofi at the beginning ...
FierceBiotech27d
Lonza's Synaffix adds Boehringer to its constellation of partners with $1.3B ADC tech pact
Under a new licensing pact, Synaffix will grant Boehringer Ingelheim access to its bespoke ADC technologies for an "agreed but undisclosed number of targets." The first target was decided by the ...
Yahoo Finance29d
Sutro Biopharma and Boehringer Ingelheim BioXcellenceâ„¢ collaboration: Established first-in-class cell-free capabilities at commercial scale
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro’s proprietary ...
Yahoo Finance27d
Boehringer Ingelheim broadens oncology portfolio with license for Synaffix's ADC technology
AMSTERDAM, BASEL, Switzerland and INGELHEIM, Germany, Jan. 9, 2025 /PRNewswire/ -- Boehringer Ingelheim and Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its ...
Business Insider20d
Boehringer provides update on iclepertin Phase III program in schizophrenia
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints ...